Table 18 Characteristics of included studies- skin cancer
From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Reinau D [235], 2015, UK | M/F | 1995–2013 | GPRD | 73,262 | 96,854 | Skin cancer | Prescription database | Last prescription ≤ 1 year before the index date(current user) | 3,6,10, 29,43,47,48,49,50,51,52 | 8 |
Johannesdottir SA [236], 2012, Denmark | M/F | 1991–2009 | Population from northern Denmark | 18,532 | 178,655 | Skin cancer | Prescription records | Redeemed > 2 prescriptions during the entire study period | 1,2,20,44,45,46 | 8 |
Torti DC [237], 2011, US | M/F | 1997–2000 | Population from New Hampshire and bordering regions | 1022 | 1484 | Skin cancer | Interview | Use at least four times a week for at least 1 month | 1,2,3,53,54,55 | 8 |
Curiel-Lewandrowski C [238], 2011, US | M/F | 2004–2007 | Dana Farber Harvard Cancer Center Institutions and Dermatology Associates of Concord, Boston(USA) | 400 | 600 | Cutaneous melanoma | Telephone interview | Use at least once weekly within a year preceding the interview (current user) | 56 | 8 |
Jeter JM [239], 2011, US | M/F | 2000–2003 | The GEM study | 327 | 119 | Melanoma | Self-reported | Daily basis for at least 3 months | 1,2,4,53,57 | 6 |
Asgari MM [240], 2010, US | M/F | 1994–2004 | KPNC | 415 | 415 | Cutaneous squamous sell sarcinoma | Questionnaire | Use at least once a week for at least 1 year(regular) | 3,4,5,30,53,56,58,59,60,61,62,63,64,65,66,67,68 | 8 |
Cohort studies | ||||||||||
Hollestein LM [91], 2014, Netherlandsa | M/F | 1998–2010 | PHARMO and the Eindhoven Cancer Registry | 2363 | 109,276 | Skin cancer | Prescription database | Low dose aspirin (≤ 100 mg daily)- not further defined | 1,2,11,12 | 8 |
Wysong A [241], 2014, US | F | 1993–1998 | WHI | 7652 | 54,728 | Non-melanoma skin cancer | Questionnaire | Use ≥ 2 times/week for at least 2 weeks(regular) | 1,3,5,7,10,14,15,19,21,29,43,69,70,71,72,73,74 | 6 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 585 | 142,330 | Melanoma | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,10,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37 | 9 |
Jeter JM [242], 2012, US | F | 1980–2008 | NHS | 17,074 | 92,125 | Skin cancer | Questionnaire | Use at least 1–2 tablets/week or 1 day/week of regular use at any lifetime(current user) | 1,3,4,7,10,14,15,54,57,75,76,77,78,79 | 7 |
Cahoon EK [243], 2012, US | M/F | 1994–1998 2003–2005 | United States Radiologic Technologists study | 2215 | 58,213 | Basal cell carcinoma | Questionnaire | Use at least 1 days per month in the past year | 1,2,80 | 8 |
Asgari MM [244], 2008, US | M/F | 2000–2005 | The VITAL cohort | 216 | 39,909 | Melanoma | Questionnaire | Use at least once a week for a year in the 10-year period before baseline(ever use) | 1,2,4,5,7,15,29, 30,56,59,69,73,81,82,83 | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 1049 | 146,113 | Melanoma | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,10,13,14,18,19,36,38,39,40,41,42 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 69 | 12,668 | Melanoma | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |